{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T06:50:11Z","timestamp":1773211811902,"version":"3.50.1"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,9,17]],"date-time":"2019-09-17T00:00:00Z","timestamp":1568678400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/K015052\/1"],"award-info":[{"award-number":["MR\/K015052\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Bone Oncology"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.jbo.2019.100261","type":"journal-article","created":{"date-parts":[[2019,9,18]],"date-time":"2019-09-18T01:41:42Z","timestamp":1568770902000},"page":"100261","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["An exploratory randomized-controlled trial of the efficacy of the Src-kinase inhibitor saracatinib as a novel analgesic for cancer-induced bone pain"],"prefix":"10.1016","volume":"19","author":[{"given":"Sarah","family":"Danson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew R","family":"Mulvey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lesley","family":"Turner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janet","family":"Horsman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"KJane","family":"Escott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert E","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sam H","family":"Ahmedzai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael I","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Andrew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbo.2019.100261_bib0001","doi-asserted-by":"crossref","first-page":"6243s","DOI":"10.1158\/1078-0432.CCR-06-0931","article-title":"Clinical features of metastatic bone disease and risk of skeletal morbidity","volume":"12","author":"Coleman","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jbo.2019.100261_bib0002","first-page":"2631","article-title":"Management of metastatic bone disease for diagnostics and treatment","volume":"36","author":"Jehn","year":"2016","journal-title":"Anticancer Res"},{"key":"10.1016\/j.jbo.2019.100261_bib0003","unstructured":"https:\/\/www.cancerresearchuk.org\/sites\/default\/files\/cs_report_world.pdf, 2014."},{"key":"10.1016\/j.jbo.2019.100261_bib0004","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/ejn.12462","article-title":"The neurobiology of skeletal pain","volume":"39","author":"Mantyh","year":"2014","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.jbo.2019.100261_bib0005","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1126\/science.288.5472.1765","article-title":"Neuronal plasticity: increasing the gain in pain","volume":"288","author":"Woolf","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.jbo.2019.100261_bib0006","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1523\/JNEUROSCI.06-05-01433.1986","article-title":"Relative effectiveness of C primary afferent fibers of different origins in evoking a prolonged facilitation of the flexor reflex in the rat","volume":"6","author":"Woolf","year":"1986","journal-title":"J. Neurosci."},{"key":"10.1016\/j.jbo.2019.100261_bib0007","doi-asserted-by":"crossref","first-page":"10886","DOI":"10.1523\/JNEUROSCI.19-24-10886.1999","article-title":"Neurochemical reorganization of the spinal cord in a murine model of bone cancer pain","volume":"19","author":"Schwei","year":"1999","journal-title":"J. Neurosci."},{"key":"10.1016\/j.jbo.2019.100261_bib0008","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.pain.2003.08.002","article-title":"Alterations in dorsal horn neurones in a rat model of cancer-induced bone pain","volume":"106","author":"Urch","year":"2003","journal-title":"Pain"},{"key":"10.1016\/j.jbo.2019.100261_bib0009","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1744-8069-6-38","article-title":"Bone cancer induces a unique central sensitization through synaptic changes in a wide area of the spinal cord","volume":"6","author":"Yanagisawa","year":"2010","journal-title":"Mol. Pain"},{"key":"10.1016\/j.jbo.2019.100261_bib0010","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nrn1368","article-title":"Src kinases: a hub for NMDA receptor regulation","volume":"5","author":"Salter","year":"2004","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.jbo.2019.100261_bib0011","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1742-4658.2011.08390.x","article-title":"Dysregulated Src upregulation of NMDA receptor activity: a common link in chronic pain and schizophrenia","volume":"279","author":"Salter","year":"2012","journal-title":"FEBS J."},{"key":"10.1016\/j.jbo.2019.100261_bib0012","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/j.1460-9568.2010.07351.x","article-title":"Glutamate receptor phosphorylation and trafficking in pain plasticity in spinal cord dorsal horn","volume":"32","author":"Liu","year":"2010","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.jbo.2019.100261_bib0013","first-page":"629","article-title":"Src family kinases: modulators of neurotransmitter receptor function and behaviour","volume":"34","author":"Ohnishi","year":"2011","journal-title":"TINS"},{"key":"10.1016\/j.jbo.2019.100261_bib0014","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1213\/01.ANE.0000081061.12235.55","article-title":"The role of N-methyl-D-aspartate (NMDA) receptors in pain: a review","volume":"97","author":"Petrenko","year":"2003","journal-title":"Anesth. Analg."},{"key":"10.1016\/j.jbo.2019.100261_bib0015","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1038\/nm.1883","article-title":"Treatment of inflammatory and neuropathic pain by uncoupling Src from the NMDA receptor complex","volume":"12","author":"Liu","year":"2008","journal-title":"Nat. Med."},{"key":"10.1016\/j.jbo.2019.100261_bib0016","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1744806916643725","article-title":"Effects of Src-kinase inhibition in cancer-induced bone pain","volume":"12","author":"de Felice","year":"2016","journal-title":"Mol. Pain"},{"key":"10.1016\/j.jbo.2019.100261_bib0017","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1359\/jbmr.090830","article-title":"Effects of the Src kinase inhibitor saracatinib (AZD0530) on bone turnover in healthy men: a randomized, double-blind, placebo-controlled multiple-ascending-dose Phase I trial","volume":"25","author":"Hannon","year":"2010","journal-title":"J. Bone Min. Res."},{"key":"10.1016\/j.jbo.2019.100261_bib0018","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.bone.2011.12.017","article-title":"Effects of Src kinase inhibition by saracatinib (AZD0530) on bone turnover in advanced malignancy in a Phase I study","volume":"50","author":"Hannon","year":"2012","journal-title":"Bone"},{"key":"10.1016\/j.jbo.2019.100261_bib0019","first-page":"129","article-title":"Pain assessment: global use of the brief pain inventory","volume":"23","author":"Cleeland","year":"1994","journal-title":"Ann. Acad. Med. Singap."},{"key":"10.1016\/j.jbo.2019.100261_bib0020","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.jbo.2019.100261_bib0021","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/j.ejca.2008.11.013","article-title":"The European organization for research and treatment of cancer quality of life questionnaire for patients with bone metastases: the EORTC QLQ-BM22","volume":"45","author":"Chow","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.jbo.2019.100261_bib0022","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/pst.185","article-title":"Sample size of 12 per group rule of thumb for a pilot study","volume":"4","author":"Julious","year":"2005","journal-title":"Pharmaceut. Statist."},{"key":"10.1016\/j.jbo.2019.100261_bib0023","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S0304-3959(00)00339-0","article-title":"Defining the clinically important difference in pain outcome measures","volume":"88","author":"Farrer","year":"2000","journal-title":"Pain"},{"key":"10.1016\/j.jbo.2019.100261_bib0024","doi-asserted-by":"crossref","first-page":"4876","DOI":"10.1158\/1078-0432.CCR-10-0748","article-title":"Phase I safety, pharmacokinetics and inhibition of Src activity study of saracatinib in patients with solid tumours","volume":"16","author":"Baselga","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jbo.2019.100261_bib0025","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1158\/1541-7786.MCR-08-0219","article-title":"The Src inhibitor AZD0530 reversibly inhibits the formation and activity of human osteoclasts","volume":"7","author":"de Vries","year":"2009","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.jbo.2019.100261_bib0026","first-page":"249","article-title":"Phase II study of saracatinib (AZD0530) for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC)","volume":"31","author":"Fury","year":"2011","journal-title":"Anticancer Res."},{"key":"10.1016\/j.jbo.2019.100261_bib0027","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s10637-012-9897-4","article-title":"Phase II study of the src kinase inhibitor saracatinib (AZD0530) in metastatic melanoma","volume":"31","author":"Gangadhar","year":"2013","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.jbo.2019.100261_bib0028","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.lungcan.2015.04.008","article-title":"A Phase II study of saracatinib (AZD0530), a src inhibitor, administered orally daily to patients with advanced thymic malignancies","volume":"89","author":"Gubens","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jbo.2019.100261_bib0029","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.clbc.2011.03.021","article-title":"Phase II trial of saracatinib (AZD0530), an oral SRC-inhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancer","volume":"11","author":"Gucalp","year":"2011","journal-title":"Clin. Breast Cancer"},{"key":"10.1016\/j.jbo.2019.100261_bib0030","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1038\/bjc.2012.158","article-title":"Phase I study of saracatinib (AZD0530) in combination with paclitaxel and\/or carboplatin in patients with solid tumours","volume":"106","author":"Kaye","year":"2012","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jbo.2019.100261_bib0031","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/CAD.0b013e328325a867","article-title":"A Phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study","volume":"20","author":"Lara","year":"2009","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.jbo.2019.100261_bib0032","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.cllc.2013.08.001","article-title":"A Phase II trial of saracatinib, an inhibitor of Src kinases, in previously-treated non-small cell lung cancer: the Princess Margaret Hospital Phase II consortium","volume":"15","author":"Laurie","year":"2014","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.jbo.2019.100261_bib0033","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1007\/s10637-011-9650-4","article-title":"A Phase II trial of the Src kinase inhibitor saracatinib (AZD0530) in patients with metastatic or locally advanced gastric or gastro esophageal junction (GEJ) adenocarcinoma: a trial of the PMH Phase II consortium","volume":"30","author":"Mackay","year":"2012","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.jbo.2019.100261_bib0034","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1093\/annonc\/mdu363","article-title":"A randomized, placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer","volume":"25","author":"McNeish","year":"2014","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jbo.2019.100261_bib0035","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.lungcan.2014.03.004","article-title":"A Phase II trial of the Src-kinase inhibitor saracatinib after four cycles of chemotherapy for patients with extensive stage small cell lung cancer: NCCTG trial N-0621","volume":"85","author":"Molina","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jbo.2019.100261_bib0036","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/pros.23119","article-title":"Saracatinib as a metastasis inhibitor in metastatic castration-resistant prostate cancer: a university of Chicago phase 2 consortium and DOD\/PCF prostate cancer clinical trials consortium study","volume":"76","author":"Posadas","year":"2016","journal-title":"Prostate"},{"key":"10.1016\/j.jbo.2019.100261_bib0037","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1093\/annonc\/mdw014","article-title":"A randomized, double-blind Phase II study evaluating cediranib versus cediranib and saracatinib in patients with relapsed metastatic clear-cell renal cancer (COSAK)","volume":"27","author":"Powles","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jbo.2019.100261_bib0038","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1007\/s10637-015-0257-z","article-title":"Phase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancer","volume":"33","author":"Reddy","year":"2015","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.jbo.2019.100261_bib0039","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s10637-010-9611-3","article-title":"A Phase I\/II study of the Src inhibitor saracatinib (AZD0530) in combination with gemcitabine in advanced pancreatic cancer","volume":"30","author":"Renouf","year":"2012","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.jbo.2019.100261_bib0040","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13195-015-0119-0","article-title":"A phase Ib multiple ascending dose study of the safety, tolerability, and central nervous system availability of AZD0530 (saracatinib) in Alzheimer's disease","volume":"7","author":"Nygaard","year":"2015","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.jbo.2019.100261_bib0041","first-page":"1393","article-title":"Characterization of cancer-induced bone pain: an exploratory study","volume":"19","author":"Laird","year":"2011","journal-title":"Support. Cancer Care"},{"key":"10.1016\/j.jbo.2019.100261_bib0042","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ejpain.2011.05.002","article-title":"Quantitative sensory testing to assess the sensory characteristics of cancer-induced bone pain after radiotherapy and potential clinical biomarkers of response","volume":"16","author":"Scott","year":"2012","journal-title":"Eur. J. Pain"},{"key":"10.1016\/j.jbo.2019.100261_bib0043","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1083\/jcb.119.4.1003","article-title":"Osteoclasts express high levels of pp60c-src in association with intracellular membranes","volume":"119","author":"Horne","year":"1992","journal-title":"J. Cell Bio.l"},{"key":"10.1016\/j.jbo.2019.100261_bib0044","first-page":"241","article-title":"Investigations of the expression of the cellular src gene product","volume":"17","author":"Brugge","year":"1986","journal-title":"Princess Takamatsu Symp"},{"key":"10.1016\/j.jbo.2019.100261_bib0045","article-title":"Bisphosphonates for the relief of pain secondary to bone metastases","volume":"2","author":"Wong","year":"2002","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.jbo.2019.100261_bib0046","first-page":"679","article-title":"Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors","volume":"22","author":"Henry","year":"2014","journal-title":"Supp. Care Cancer"},{"key":"10.1016\/j.jbo.2019.100261_bib0047","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1007\/s00198-011-1856-y","article-title":"The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures","volume":"23","author":"Hadji","year":"2012","journal-title":"Osteoporos Int."},{"key":"10.1016\/j.jbo.2019.100261_bib0048","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1016\/j.ejca.2012.08.002","article-title":"Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomized, phase 3 trials","volume":"48","author":"Lipton","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.jbo.2019.100261_bib0049","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/0092-8674(91)90499-O","article-title":"Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice","volume":"64","author":"Soriano","year":"1991","journal-title":"Cell"},{"key":"10.1016\/j.jbo.2019.100261_bib0050","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.bone.2007.08.029","article-title":"Genetics, pathogenesis and complications of osteopetrosis","volume":"42","author":"del Fattore","year":"2008","journal-title":"Bone"},{"key":"10.1016\/j.jbo.2019.100261_bib0051","doi-asserted-by":"crossref","first-page":"28011","DOI":"10.1074\/jbc.M605865200","article-title":"c-Src control of chloride channel support for osteoclast HCl transport and bone resorption","volume":"281","author":"Edwards","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jbo.2019.100261_bib0052","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/5971","article-title":"Activating Src mutation in a subset of advanced human colon cancers","volume":"21","author":"Irby","year":"1999","journal-title":"Nature Genet"},{"key":"10.1016\/j.jbo.2019.100261_bib0053","doi-asserted-by":"crossref","first-page":"328ra30","DOI":"10.1126\/scitranslmed.aad7666","article-title":"A dominant gain-of-function mutation in universal tyrosine kinase Src causes thrombocytopenia, myelofibrosis, bleeding, and bone pathologies","volume":"8","author":"Turro","year":"2016","journal-title":"Sci. Transl. Med."}],"container-title":["Journal of Bone Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212137419301691?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212137419301691?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T20:17:23Z","timestamp":1761941843000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212137419301691"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":53,"alternative-id":["S2212137419301691"],"URL":"https:\/\/doi.org\/10.1016\/j.jbo.2019.100261","relation":{},"ISSN":["2212-1374"],"issn-type":[{"value":"2212-1374","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An exploratory randomized-controlled trial of the efficacy of the Src-kinase inhibitor saracatinib as a novel analgesic for cancer-induced bone pain","name":"articletitle","label":"Article Title"},{"value":"Journal of Bone Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbo.2019.100261","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}],"article-number":"100261"}}